9 / 24
International partnerships with
centres in Kenya, Ethiopia, Ghana,
Jordan, India, Spain, Qatar
For more information, please visit
www.thepmcf.caor call
416-946-6560
.
ONE OF THE TOP 5 CANCER RESEARCH CENTRES IN THE WORLD
200+ types of cancer treated
including many of Canada’s
most complex and rare cases
SCIENTIFIC
SUPER STAR
• Stem cells
• Cloning T-cell receptor
• Colon cancer stem cells
• Lung cancer gene signature
• Blood stem cell
• Root cause of myeloma
relapse
• A new view of how
blood is made
Dr. Tak Mak
Brilliant researcher,
cloned the T-cell
receptor and developed
first-in-class cancer
drug, cited over
75,000 times
IMAGE-GUIDED
THERAPEUTICS
ROCK STAR
Dr. David Jaffray
World leader in
image-guided radiation
with 5 patents issued,
has won most major
prizes in medical physics,
founding Director of
Techna Institute
Dr. Mary Gospodarowicz
Medical Director of
The Princess Margaret,
Globally recognized
radiation oncologist,
researcher and mentor,
1
st
Canadian and 1
st
female
President of Union for
International Cancer Control
GLOBAL ONCOLOGY
LEADER
Canada's largest and one
of the world's top-rated
clinical trial programs
1 in 5 patients
participating in
a clinical trial
PRINCESSMARGARET CANCER CENTRE
RESEARCH
PERFORMANCE
SCALE
TRACK
RECORD
BREADTH
388,588
ft
2
Research Space
10 floors at Princess Margaret Cancer Research Tower and
3 floors at Princess Margaret Cancer Centre are dedicated
to research. This is larger than five soccer fields combined.
Canada’s largest surgical
oncology team and one of
the largest in the world
Canada’s first centre to use
genetic “fingerprints” to precisely
diagnose patient cancers
Over
1
,
200
people
employed in our research
enterprise, including
WORLD FIRSTS
Cancers Treated
200+
Cancer Genomics,
Epigenetics and
Bioinformatics
Stem Cells
in Cancer
Bio Discovery
and Drug
Development
Immunotherapy
Tumor Biology
and Imaging
The world's largest
single-site radiation
medicine program
18,033
new patients a year
A WORLD
LEADER
450
Trainees
64
Scientists
315
Clinical
Researchers
Ranks 4th for percentage of papers
published in high-impact oncology journals,
and 4th for percentage of highly cited papers